Treatment of tumor-bearing mice with this novel combination therapy resulted in efficacious tumor growth control, increased numbers of activated CD8+ T cells and tumor-specific cytotoxicity, and an increased in resistance to subsequent tumor challenge and metastatic tumor growth. This evidence concerns the gene CD8A and neoplasm.